戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ently, allelic loss) occur in tumors in FAP (familial adenomatous polyposis).
2 pared with either drug alone, in adults with familial adenomatous polyposis.
3  that of patients with classic or attenuated familial adenomatous polyposis.
4 d several cancers such as retinoblastoma and familial adenomatous polyposis.
5 sporadic tumors or in tumors associated with familial adenomatous polyposis.
6 the development of adenomas in subjects with familial adenomatous polyposis.
7 osis coli gene (APC) that is associated with familial adenomatous polyposis.
8 size 5 mm; range 1-13 mm) from patients with familial adenomatous polyposis.
9 fr) signaling on the Apc(Min) mouse model of familial adenomatous polyposis.
10 s in the treatment of ulcerative colitis and familial adenomatous polyposis.
11 on/activity in the Apc(Min/+) mouse model of familial adenomatous polyposis.
12 lastic role in the Apc(Min/+) mouse model of familial adenomatous polyposis.
13  (APC) allele can lead to the development of familial adenomatous polyposis.
14 rcinoma and causes regression of adenomas in familial adenomatous polyposis.
15 PAA), 1 had indeterminate colitis, and 8 had familial adenomatous polyposis.
16 mas, but do not have the florid phenotype of familial adenomatous polyposis.
17 bitor, on colorectal polyps in patients with familial adenomatous polyposis.
18 mber and size of adenomas in mouse models of familial adenomatous polyposis.
19 osses with ApcMin/+, a murine model of human familial adenomatous polyposis.
20 testinal tumor formation in a mouse model of familial adenomatous polyposis.
21 ous polyposis coli (APC) gene that underlies familial adenomatous polyposis.
22 urrence of colonic adenomas in patients with familial adenomatous polyposis.
23 the adenoma phenotype in this mouse model of familial adenomatous polyposis.
24 e number and size of polyps in patients with familial adenomatous polyposis.
25 hereditary conditions like Lynch Syndrome or Familial Adenomatous Polyposis.
26  indication, inflammatory bowel disease, and familial adenomatous polyposis.
27 lorectal cancers and tumors in patients with familial adenomatous polyposis.
28 omas (123 samples) from six individuals with familial adenomatous polyposis.
29 ent APC(Min/+) mice, a murine model of human Familial Adenomatous Polyposis.
30 ired biopsies from IPAA patients with UC and familial adenomatous polyposis.
31 ange, which are similar to those observed in familial adenomatous polyposis.
32 oli (APC) is associated with pathogenesis of familial adenomatous polyposis.
33 the leading causes of death in patients with familial adenomatous polyposis.
34 r interact with Apc, are important models of familial adenomatous polyposis.
35 al adenoma development in an animal model of familial adenomatous polyposis.
36 ally or in combination in an animal model of familial adenomatous polyposis.
37       Min mice provide a good model of human familial adenomatous polyposis.
38 ects had pathogenic variants associated with familial adenomatous polyposis.
39 Wnt pathway or APC gene mutations that cause familial adenomatous polyposis.
40  for the treatment of ulcerative colitis and familial adenomatous polyposis.
41 mphocyte depletion observed in this model of familial adenomatous polyposis.
42 colorectal cancer [such as Lynch syndrome or familial adenomatous polyposis]).
43   Diagnosis (chronic ulcerative colitis 97%, familial adenomatous polyposis 3%) and previous operativ
44 ugh studies of hereditary syndromes, such as familial adenomatous polyposis, a cancer predisposition
45 smaller median number of polyps than typical familial adenomatous polyposis, a wide variability in po
46 re also detected in APC(min) mouse and human familial adenomatous polyposis adenomas compared with no
47  pouch/ileum, CDP, pouchitis, and those with familial adenomatous polyposis after pouch formation.
48                                Patients with familial adenomatous polyposis after pouch surgery (n =
49 hers syndrome and the phenotypic features of familial adenomatous polyposis aid significantly in synd
50 r protein, germline mutation of which causes familial adenomatous polyposis, an autosomal intestinal
51            Using colectomy specimens from 16 familial adenomatous polyposis and 11 control cases, we
52                     Germline mutations cause familial adenomatous polyposis and at least two-thirds o
53 plications for dietary intervention in human familial adenomatous polyposis and colon cancer.
54 ajor syndromes related to colorectal cancer, familial adenomatous polyposis and hereditary non-polypo
55 al dominant hereditary forms of the disease, familial adenomatous polyposis and hereditary nonpolypos
56 ion of preexisting adenomas in patients with familial adenomatous polyposis and significantly inhibit
57  prevention of colon cancer in patients with familial adenomatous polyposis and sporadic polyps.
58 nn syndrome, Simpson-Golabi-Behmel syndrome, familial adenomatous polyposis and trisomy 18.
59 lasia type 2, von Hippel-Lindau disease, and familial adenomatous polyposis are examples of syndromes
60 elaying disease progression in patients with familial adenomatous polyposis are unknown.
61 The loss of APC function is observed in most familial adenomatous polyposis-associated and sporadic c
62                                              Familial adenomatous polyposis because of germline mutat
63  years) who were genotypically affected with familial adenomatous polyposis but phenotypically unaffe
64 y of 41 subjects genotypically affected with familial adenomatous polyposis but phenotypically unaffe
65  benefit not only in patients diagnosed with familial adenomatous polyposis but, perhaps, in other pr
66 ectomy is required for ulcerative colitis or familial adenomatous polyposis, but long-term data on fu
67 al polyp in animals and in patients with the familial adenomatous polyposis by downregulating beta-ca
68 eukemia) and inherited conditions (Lynch and familial adenomatous polyposis), by changing only 2 tiss
69 zygote Min/+ mouse model, like patients with familial adenomatous polyposis, carries a nonsense mutat
70  the inherited autosomal dominant condition, familial adenomatous polyposis, celecoxib proved efficac
71 e associated with an attenuated phenotype of familial adenomatous polyposis coli (AAPC).
72 ly recognized as a potential complication of familial adenomatous polyposis coli (APC) and attenuated
73 and multiple colonic adenomas reminiscent of familial adenomatous polyposis coli (FAP).
74 rome of colon cancer predisposition known as familial adenomatous polyposis coli (FAP).
75 lastic phenotype similar to that observed in familial adenomatous polyposis coli in humans.
76 cancer, adenomas taken from individuals with familial adenomatous polyposis contain high levels of Ct
77     Colectomy specimens from 3 patients with familial adenomatous polyposis containing polypoid and n
78                                              Familial adenomatous polyposis (FAP) and attenuated FAP
79 ncer from human inherited syndromes, such as familial adenomatous polyposis (FAP) and hereditary non-
80                  Two well-defined syndromes, familial adenomatous polyposis (FAP) and hereditary non-
81 orders predisposing to colorectal cancer are familial adenomatous polyposis (FAP) and hereditary nonp
82 e patients who had undergone colectomies for familial adenomatous polyposis (FAP) and specimens from
83 rmines the type of the 'second hit', both in familial adenomatous polyposis (FAP) and sporadic colore
84 tween phenotypic expression in patients with familial adenomatous polyposis (FAP) and the site of mut
85 n the indications of MMVTx for patients with familial adenomatous polyposis (FAP) and the technical f
86                                Patients with familial adenomatous polyposis (FAP) are at markedly inc
87 denomatous polyposis coli (APC) mutations or familial adenomatous polyposis (FAP) are born with norma
88 tients with Lynch syndrome and patients with familial adenomatous polyposis (FAP) as controls.
89 set and progression of colorectal cancers in Familial Adenomatous Polyposis (FAP) as well as residual
90  clinicopathological scenarios: sporadic and familial adenomatous polyposis (FAP) associated.
91 attern dramatically altered for the worse in familial adenomatous polyposis (FAP) because these patie
92                     We studied patients with Familial Adenomatous Polyposis (FAP) because they are vi
93 riginally identified as a candidate gene for familial adenomatous polyposis (FAP) but further study i
94    These tumors often occur in patients with familial adenomatous polyposis (FAP) coli who have germ
95 were ulcerative colitis (UC) in 37 patients, familial adenomatous polyposis (FAP) in 12 patients, and
96 incidence of thyroid cancer in patients with Familial adenomatous polyposis (FAP) in a prospective st
97                                              Familial adenomatous polyposis (FAP) is a human cancer s
98                                              Familial adenomatous polyposis (FAP) is a rare autosomal
99                                              Familial adenomatous polyposis (FAP) is an autosomal dom
100                                              Familial adenomatous polyposis (FAP) is an autosomal-dom
101                                              Familial adenomatous polyposis (FAP) is caused by a domi
102                                              Familial Adenomatous Polyposis (FAP) is characterized by
103 the familial cancer predispositions known as familial adenomatous polyposis (FAP) or Gardner syndrome
104 tudied methylation in ACF from patients with familial adenomatous polyposis (FAP) or sporadic colorec
105 tations in colonic and duodenal tumours from familial adenomatous polyposis (FAP) patients has shown
106 of the earliest colonic tissue alteration in familial adenomatous polyposis (FAP) patients, we presen
107 f adenomas after 4-6 months of treatment for familial adenomatous polyposis (FAP) patients.
108 multiple intestinal neoplasia (Min) mice and familial adenomatous polyposis (FAP) patients.
109  commercial availability of gene testing for familial adenomatous polyposis (FAP) represents an impor
110 a pancreatoblastoma in an adult patient with familial adenomatous polyposis (FAP) suggests that they
111  mucosa from an XO/XY mosaic individual with familial adenomatous polyposis (FAP) was examined direct
112 abecular bone abnormalities in patients with familial adenomatous polyposis (FAP) were evaluated usin
113 tions in APC are classically associated with familial adenomatous polyposis (FAP), a highly penetrant
114 in, germline mutation of which characterizes familial adenomatous polyposis (FAP), an autosomal intes
115 in Adenomatous polyposis coli (APC) underlie familial adenomatous polyposis (FAP), an inherited cance
116 l ulcerative colitis, indeterminate colitis, familial adenomatous polyposis (FAP), and a select group
117 ssor gene APC are associated with hereditary familial adenomatous polyposis (FAP), and somatic mutati
118 tary nonpolyposis colorectal cancer (HNPCC), familial adenomatous polyposis (FAP), and sporadic CRC.
119                                              Familial adenomatous polyposis (FAP), due to germ-line m
120 arbor an inherited predisposition, including familial adenomatous polyposis (FAP), hereditary nonpoly
121 e frequently present in FGPs associated with familial adenomatous polyposis (FAP), raising the possib
122 m, combinatorial chemoprevention efficacy in familial adenomatous polyposis (FAP), signal of benefit
123 y (Family N) with symptoms characteristic of familial adenomatous polyposis (FAP), which is typically
124 way is a hallmark of many cancers, including familial adenomatous polyposis (FAP)-related desmoid tum
125 as well as DNA of individuals diagnosed with familial adenomatous polyposis (FAP).
126  in APC(Min/+) mice, a murine model of human familial adenomatous polyposis (FAP).
127  most common gastric polyps in patients with familial adenomatous polyposis (FAP).
128 s coli (APC) tumor-suppressor gene result in familial adenomatous polyposis (FAP).
129  APC promoter 1B occur in rare families with familial adenomatous polyposis (FAP).
130 pment of intestinal adenomas associated with familial adenomatous polyposis (FAP).
131 al anastomosis (IPAA) done for patients with familial adenomatous polyposis (FAP).
132 but can occur in up to 21 % of patients with Familial Adenomatous Polyposis (FAP).
133 eoplasia type 2 (MEN2), Cowden syndrome, and familial adenomatous polyposis (FAP).
134 number of colorectal polyps in children with familial adenomatous polyposis (FAP).
135 e orthologous to those responsible for human familial adenomatous polyposis (FAP).
136 tion of colorectal adenomas in patients with familial adenomatous polyposis (FAP).
137 opic evaluation, especially in patients with familial adenomatous polyposis (FAP).
138 strategy to iPSCs derived from patients with familial adenomatous polyposis (FAP-iPSCs) harboring ger
139 ith ulcerative colitis (UC) versus controls (familial adenomatous polyposis [FAP]).
140  APC-mutation-negative probands with classic familial adenomatous polyposis (>100 adenomas).
141                        An attenuated form of familial adenomatous polyposis has been described, but t
142  history of polyp formation in patients with familial adenomatous polyposis has provided a benchmark
143 ereditary nonpolyposis colorectal cancer and familial adenomatous polyposis has provided insight into
144                             Individuals with familial adenomatous polyposis have a germline heterozyg
145                                Patients with familial adenomatous polyposis have a nearly 100 percent
146 ition, clinical studies of the human disease familial adenomatous polyposis have demonstrated the eff
147 olyposis coli gene, which is responsible for familial adenomatous polyposis, have been described in p
148 ystic Fibrosis, Duchenne Muscular Dystrophy, Familial Adenomatous Polyposis, Hereditary Non-polyposis
149 romes such as multiple endocrine neoplasias, familial adenomatous polyposis, hereditary nonpolyposis
150                      These syndromes include familial adenomatous polyposis, hereditary nonpolyposis
151 r ulcerative colitis in 73% of the cases and familial adenomatous polyposis in 17%.
152 Celecoxib is prescribed for the treatment of familial adenomatous polyposis in humans, and the CEA-ba
153 amilial adenomatous polyposis mimics typical familial adenomatous polyposis in some cases but in othe
154     This investigation shows that attenuated familial adenomatous polyposis in the kindreds examined
155 ents with sporadic colorectal carcinomas and familial adenomatous polyposis, in 18 sporadic HPs from
156  colon adenomas recovered from patients with familial adenomatous polyposis, including adenomas as sm
157 ereditary nonpolyposis colorectal cancer and familial adenomatous polyposis, indicates that mutations
158                                              Familial adenomatous polyposis is an autosomal dominant
159                                              Familial adenomatous polyposis is an inherited genetic d
160                                              Familial adenomatous polyposis is caused by a germ-line
161 r tracks) and multiple POFLs associated with familial adenomatous polyposis is reviewed.
162 testing on 810 individuals from 2 attenuated familial adenomatous polyposis kindreds harboring an ide
163                  The phenotype of attenuated familial adenomatous polyposis mimics typical familial a
164 herited syndromes, including Lynch syndrome, familial adenomatous polyposis, MUTYH-associated polypos
165 ets in intestinal tissues from patients with familial adenomatous polyposis (n = 18) or sessile serra
166 (n = 10), and normal pouch from patient with familial adenomatous polyposis (n = 6).
167  adenomas (n = 18), adenomas associated with familial adenomatous polyposis (n = 7), hyperplastic pol
168                     Sex, age at diagnosis of familial adenomatous polyposis, number of polyps at firs
169 (the adenomatous polyposis coli gene) causes familial adenomatous polyposis of the colorectum.
170 d IPAA procedures for ulcerative colitis and familial adenomatous polyposis, of which all but 2 were
171     Patients who underwent genetic tests for familial adenomatous polyposis often received inadequate
172 lear-cut inherited Mendelian traits, such as familial adenomatous polyposis or hereditary nonpolyposi
173 uished clinically from cases with attenuated familial adenomatous polyposis or MUTYH-associated polyp
174 ested, 83.0 percent had clinical features of familial adenomatous polyposis or were at risk for the d
175 yndromes associated with thyroid cancer (eg, familial adenomatous polyposis), or one or more first-de
176               A diagnosis of Lynch syndrome, familial adenomatous polyposis, or another genetic syndr
177 oids, shCtBP2 knockdown in LS174T cells, and familial adenomatous polyposis patient-derived organoids
178 ation of the premalignant crypt phenotype in familial adenomatous polyposis patients, the hypothesis
179                                              Familial adenomatous polyposis patients, who have a germ
180 e that closely simulates that found in human familial adenomatous polyposis patients.
181                            Compared with the familial adenomatous polyposis pouch, the UC pouch was e
182       Ectopic expression of APC, but not its familial adenomatous polyposis-related truncation mutant
183                       A mouse model of human Familial Adenomatous Polyposis responds favorably to pha
184 nampullary duodenal adenomas associated with familial adenomatous polyposis should be considered for
185                             In patients with familial adenomatous polyposis, six months of twice-dail
186                          In murine models of familial adenomatous polyposis, specifically the multipl
187                 Studies of tumors from human familial adenomatous polyposis, sporadic colon cancer, a
188 rectal adenomas in animals and patients with familial adenomatous polyposis suggest that COX-2 inhibi
189 r at increased frequency among patients with familial adenomatous polyposis, suggesting that alterati
190                 In this study, using a human familial adenomatous polyposis syndrome susceptible mous
191 ilar to most mutations observed in the human familial adenomatous polyposis syndrome.
192 hereditary nonpolyposis colorectal cancer or familial adenomatous polyposis syndromes.
193  in the majority of the 30% of patients with familial adenomatous polyposis that do not test positive
194        In this trial involving patients with familial adenomatous polyposis, the incidence of disease
195 hogenic constitutional APC variants underlie familial adenomatous polyposis, the most common heredita
196  genetic diseases, three females (1.6 %) had familial adenomatous polyposis; three patients (1 male a
197 th mutation-negative Lynch syndrome, 16 with familial adenomatous polyposis, two with constitutional
198  polyps from a 16-year-old male patient with familial adenomatous polyposis was insufflated, submerge
199 sis sulindac sulfide, which is used to treat familial adenomatous polyposis, was selected to detect g
200  for patients with indeterminate colitis and familial adenomatous polyposis were inconclusive because
201 intestinal neoplasia mice (a model for human familial adenomatous polyposis) were crossed with cyclin
202                                Patients with familial adenomatous polyposis who take NSAIDs, such as
203  patients with inflammatory bowel disease or familial adenomatous polyposis who underwent IAPT by a s

 
Page Top